Skip to main content

News

Updated RA Treat-to-Target International Recommendations

In 2010, Smolen and a group of international rheumatologists developed a series of recommendations addressing the concept of treat-to-target (T2T) in the management of rheumatoid arthritis (RA).

Risk of Multiple Sclerosis with TNF Inhibitor Therapy

Researchers from the DANBIO registry have linked their registry of 30,033 arthritis patients with the Danish Multiple Sclerosis Registry (DMSR) to identify all new multiple sclerosis cases occuring in arthritis patients and those receiving TNF inhibitors (TNFi). 

Biosimilar Reports - January 2016

Biosimilars are the fastest developing product line within the pharmaceutical industry. There is unanimous worldwide interest in the continued use of biologics for immune mediated disorders.

UK Audit Shows Early RA Referrals Still Too Slow

A national audit of rheumatoid arthritis (RA) and early inflammatory arthritis patients included 6,354 patients drawn from 143 trusts and health boards in England and Wales. Early arthritis clinics exist in 57% of trusts.

PML is Very Rare in Lupus

A systematic review of the literature was done to assess the relationship between immunosuppressive therapy, adult systemic lupus erythematosus (SLE) and the onset of progressive multifocal leukoencephalopathy.

TNF Inhibitors May Increase Cardiac Risks in Elderly

A retrospective study of elderly rheumatoid arthritis (RA) patients on Medicare was conducted by a group of researchers from the University of Alabama.

ASBMR Guidance on Bisphosphonate Use

The American Society of Bone and Mineral Research (ASBMR) Task Force has issued a guidance report on the use of bisphosphonates (BP) with a focus on the risk vs. benefits of such therapy. (Citation source http://buff.ly/1Nn0CVb)

PALACE 3 Study: Apremilast Shows 52 Wk. Efficacy in Active Psoriatic Arthritis

Apremilast, a novel phosphodiesterase 4 (PDE4) inhibiting conversion of cyclic AMP to AMP, was approved for treatment of psoriatic arthritis (PsA) after showing its efficacy in 16 weeks PALACE 1, 2, and 3 trials in 2014.

10 Ways Rheumatoid Arthritis Could’ve Killed Glenn Frey

I was truly stunned Monday when it was announced that Glenn Frey, from the Eagles, had died as a result of complications from his rheumatoid arthritis, ulcerative colitis and pneumonia.

Methotrexate Nonadherence is Common

Researchers from Belgium studied patient adherence to MTX (given orally or via injection) in 129 rheumatoid arthritis (RA) patients over a 16-week period using an electronic monitoring system and two validated adherence questionnaires.

French Cannibinoid Phase I Study Gone Wrong

Six volunteers were admitted to the University Hospital of Rennes in France last week after partaking in the Phase I trial of a new medication meant to treat mood disorders such as anxiety.

DSB Reports & Updates - January 2016

Comparative Harmful Risks with Targeted Immunomodulators. Desai et al did a systematic review of the literature, findings of 10 head-to-head RCTs and 51 observational studies.

×